Agriculture

Fair trade: Green Organic Dutchman (TGOD.T) does the hard, sensible things required to reset

Because this story is about The Green Organic Dutchman (TGOD.T) and cannabis investors bear grudges, the vast majority of people reading it will already be saying the words, “Fuck Parry, you’ll pump anything for money.”

So let’s get some things out of the way before we start. 1) TGOD isn’t paying for this story, and haven’t been a client for well over a year. 2) TGOD might not be a fan of this story

Read More »

Tilray (TLRY.Q) financials are nightmare fuel: Quarterly net loss down 16% to ‘just’ $184m

If Tilray (TLRY.Q) will leave any sort of legacy on the Canadian cannabis landscape, it will be that, for a short time and by virtue of a well-timed and paper-lined public listing, the CEO was the highest paid CEO in North America. For a hot minute, Americans bought in by the truckload and drove the shareprice up like DryShips (DRYS), making the boss a very paper rich man. Everything else the company has managed to achieve has been downhill from there.

Read More »

Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news

Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.

Read More »

Shroom stocks go nuts: First movers SHRM, MMED, RVV up hard as gamblers gamble

Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped 90% to $0.77 on the back of 15m shares traded, reminding anyone who’d listen that ex-Canopy CEO Bruce Linton and pretend billionaire Kevin O’Leary were on board. Champignon Brands (SHRM.C) zoomed 40% to $0.33 on a lot smaller market awareness spend byt a handy ticker, Roadman Investments (LITT.V) was up 30% to $0.065 being sucked along in the other two companies’ wake, and Revive Therapeutics (RVV.C) was up 81% to $0.10 on ripples caused by the rest.

Read More »

2020 Gravitas Securities Growth Conference lines up seriously interesting deals, even in weed

Respect where it’s due, I haven’t been to an investor conference in a long time where I came away interested in most of what I saw, let alone *everything* I saw, but this year’s Gravitas Securities Growth Conference lineup absolutely hit it out of the park. The GSGC isn’t the biggest show around, but they know how to turn out the playahs, and the only way you keep big money showing up is to be a little bit picky with what you offer them. Don’t waste anyone’s time and they’ll know it’s cool to return.

Read More »

1933 Industries (TGIF.C) blows up, jumps 35% preceding California harvest announcement

You’ve gotta love it when a plan comes together: 1933 Industries (TGIF.C), which has been banging the same ‘we’re grownups, we’re doing it right, hang tight’ drum for several years now, dropped news this February 14 that will make any Valentine’s heart swell with joy. “Following the completion of a combined 20,000-square-foot expanded cultivation, extraction, manufacturing and distribution facility in the Los Angeles area, the company began harvesting its first cannabis crop this week to be utilized for both its proprietary brand Alternative Medicine Association (AMA), as well as for its licensing partner luxury brand Blonde cannabis, with products earmarked for dispensaries for the first time outside of Nevada.”

Read More »

Vext Science (VEXT.C) cannabis chart defies gravity

“The core business, which is derived from an Arizona licensed vertically integrated model, generated USD $13 million in revenues during the first two quarters of 2019,” confirmed Equity Guru’s Sam Bourgi last October.

Ironically, VEXT is a healthy cannabis business, and investors are quickly gaining confidence in it.

Read More »

2019 weed wrap: The end of the cannabis cycle of cannabis cycles

Like the old Twilight Zone episode where helpful aliens leave behind a book called ‘To Serve Man’, only for us to find out later it’s a cookbook, investors have been welcomed and fattened up nicely by alpha predators as they unwittingly await their slaughter, not realizing that, they’re at the predator’s table because they’re the main course.

Read More »

Equity Guru Podcasts